According to a notice from the UK Department of Health and Social Care (DHSC), Novo Nordisk A/S (NYSE: NVO) will withdraw all forms of Levemir (insulin detemir) by the end of 2026. The DHSC has issued a National Patient Safety Alert to all healthcare systems in the UK, requiring community physicians to review prescriptions and switch patients to alternative insulins. The withdrawal follows Novo Nordisk’s September 2024 decision to discontinue production of Levemir globally, with UK supplies expected to run out by December 2026.
Policy & Product Milestone
| Item | Detail |
|---|---|
| Issuer | UK Department of Health and Social Care (DHSC) |
| Alert Type | National Patient Safety Alert to all UK healthcare systems |
| Product | Levemir (insulin detemir) – all forms |
| Manufacturer | Novo Nordisk A/S (NYSE: NVO) |
| Notice Date | 5 Oct 2026 |
| Withdrawal Deadline | End of 2026; UK supplies expected to run out by December 2026 |
| Required Action | Community physicians to review prescriptions and switch patients to alternative insulins |
| Global Context | Global production discontinuation decided by Novo Nordisk in September 2024 |
Product Profile – Levemir (Insulin Detemir)
- Drug Class: Long-acting analogue insulin, also known as a basal insulin — the background insulin coverage that suppresses hepatic glucose output between meals and overnight.
- Patient Population: Approved for use in anybody aged 1 and over.
- Duration of Action: Provides up to 24 hours of basal insulin coverage.
- Dosing Regimen: Injected once or twice a day, depending on individual glycemic needs.
- Product Generation: Considered an older insulin, with use declining worldwide — the rationale cited for global discontinuation.
Withdrawal Timeline & Transition Requirements
- September 2024: Novo Nordisk decided to discontinue production of Levemir globally, citing the product’s older-generation status and declining worldwide use.
- 2024–2026: The discontinuation process has already been under way; remaining supply is being drawn down.
- December 2026: UK supplies are expected to run out, aligning with the end-of-2026 withdrawal of all Levemir forms.
- Ongoing Requirement: Under the National Patient Safety Alert, all UK healthcare systems must ensure community physicians review prescriptions and proactively switch Levemir patients to alternative insulins before supply exhaustion — a coordinated, system-wide transition rather than reactive substitution at the point of stock-out.
Clinical Context – Basal Insulin Transition
- Why Switches Must Be Managed: Basal insulin is life-sustaining therapy for people with type 1 diabetes and many with advanced type 2 diabetes; abrupt interruption or unplanned substitution risks hyperglycemia, hypoglycemia during dose adjustment, and diabetes-related emergencies.
- Alternative Landscape: Several long-acting basal insulins — including newer analogues with ultra-long duration profiles — remain available in the UK, alongside biosimilar options; the appropriate alternative and dose conversion is an individual clinical decision.
- Safety Alert Mechanism: UK National Patient Safety Alerts obligate healthcare organizations to act within defined timescales, ensuring prescriber-led review reaches all affected patients across community settings.
- Pediatric Consideration: Because Levemir is licensed from age 1, switching plans must also cover children and adolescents on the product.
Market Impact & Outlook
- Portfolio Rationalization: The withdrawal completes Novo Nordisk’s global phase-out of an older basal insulin, concentrating the company’s diabetes franchise on newer-generation insulins and its broader cardiometabolic portfolio.
- UK Prescribing Shift: Community physicians will redistribute Levemir patients across remaining basal insulin options, with conversion decisions shaping near-term prescribing patterns in UK diabetes care.
- Supply-Chain Discipline: The DHSC alert and the December 2026 supply-out date give the health system a defined runway to complete transitions before stock exhaustion.
- Precedent for Managed Withdrawals: The coordinated alert–review–switch framework illustrates how regulators manage discontinuations of widely used chronic therapies without treatment gaps.
- Next Steps: Prescription reviews and patient switches across UK healthcare systems ahead of end-2026; alternative-product uptake and any further DHSC guidance were not detailed in the notice.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the withdrawal of Levemir (insulin detemir) in the UK, including the expected December 2026 supply exhaustion and the completion of patient transitions to alternative insulins. Actual results may differ due to risks including supply timing, prescriber and patient transition execution, alternative product availability, and further regulatory guidance. This summary is based on the DHSC notice and Novo Nordisk’s previously announced global discontinuation decision.-Fineline Info & Tech
